Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
(Approval lapsed) CRESEMBA isavuconazonium sulfate 372mg (equivalent to 200 mg isavuconazole) powder for injection vial (USA)
Section 19A approved medicine
(Approval lapsed) CRESEMBA isavuconazonium sulfate 372mg (equivalent to 200 mg isavuconazole) powder for injection vial (USA)
Section 19A approval holder
Orspec Pharma Pty Ltd ABN: 15634980417
Phone
02 4339 4239
Approved until
Status
Expired
Medicines in short supply/unavailable
CRESEMBA isavuconazole (as isavuconazonium sulfate) 200 mg powder for injection vial AUST R: 305480
Indication(s)
CRESEMBA (USA) is indicated in adults for the treatment of
- invasive aspergillosis
- invasive mucormycosis
Images
